Teprotumumab may significantly improve outcomes in patients with active thyroid eye disease
1. In this phase 3 trial, patients with thyroid eye disease who received teprotumumab were far more likely to demonstrate a proptosis response compared...
Total hip arthroplasty versus hemiarthroplasty for management of hip fractures
1. In this randomized controlled trial, the incidence of secondary procedures within 2 years did not differ significantly between patients that received a total...
Electronic health record-based weight maintenance coaching
1. This randomized controlled trial showed a mean weight difference of -2.86 kg at 24 months and -3.21 kg at 30 months in participants...
Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart...
1. In patients with stable heart failure, adrenergic co-transmitter neuropeptide Y (NPY) levels can identify patients at risk of adverse outcomes related to hyperadrenergic...
Levothyroxine not effective for treatment of subclinical hypothyroidism symptoms in geriatric patients
1. There was no significant improvement of symptoms associated with subclinical hypothyroidism when subjects aged 80 year or older were given levothyroxine versus the...
MIV-711 effective in reducing bone and cartilage manifestations for patients with osteoarthritis
1. In this double-blind phase 2a trial, cathepsin K inhibitor MIV-711 did not show a significant benefit in reducing pain but proved effective in...
Ultra-processed foods linked to increased risk of type 2 diabetes
1. In this prospective cohort study from France, consumption of ultra-processed foods (UPF) was linked to an increased risk of type 2 diabetes (T2D).2....
Integrated care for children found to improve quality of life and reduce costs
1. A meta-analysis of 23 randomized controlled trials examining the impact of integrated care interventions on health-related outcomes in children 0-18 years of age...
Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C
1. The rate of hepatitis C virus (HCV) transmission from nucleic acid amplification testing (NAT)-negative donor hearts is low, and survival rates in patients...
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X)
1. Ixekizumab, an IL-17 inhibitor, elicits disease response in patients with non-radiographic active axial spondyloarthritis who have failed treatment with NSAIDs.Evidence Rating Level: 1 (Excellent)Axial...
